{{Rsnum
|rsid=7920517
|Gene=TIMM23B
|Chromosome=10
|position=51532621
|Orientation=plus
|GMAF=0.4752
|Assembly=GRCh37.p2
|GenomeBuild=37.2
|dbSNPBuild=134
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 32.7 | 50.4 | 16.8
| HCB | 24.1 | 52.6 | 23.4
| JPT | 37.2 | 46.9 | 15.9
| YRI | 5.4 | 27.9 | 66.7
| ASW | 12.3 | 35.1 | 52.6
| CHB | 24.1 | 52.6 | 23.4
| CHD | 26.6 | 40.4 | 33.0
| GIH | 17.8 | 41.6 | 40.6
| LWK | 1.8 | 23.6 | 74.5
| MEX | 37.9 | 48.3 | 13.8
| MKK | 2.6 | 25.0 | 72.4
| TSI | 27.5 | 51.0 | 21.6
| HapMapRevision=28
}}rs7920517 increases susceptibility to Prostate cancer 1.15 times for heterozygotes (AG) and 1.99 times for homozygotes (CC) {{PMID|18264097}}

{{PMID Auto
|PMID=19900942
|Title=Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy
}}

{{PMID Auto
|PMID=19639606
|Title=Correcting "winner's curse" in odds ratios from genomewide association findings for major complex human diseases.
|OA=1
}}

{{PMID Auto
|PMID=20690139
|Title=Meta-analysis of genome-wide and replication association studies on prostate cancer.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}